High quality Desmopressin Acetates CAS NO.16789-98-3

 

Specifciation:

                             1.Competitive price
                             2.Fast Delivery Within 2 days
                             3.SGS , BV, GMP,ISO approve
                             4.Professional factory

GMP factory supply high quality Desmopressin Acetate 16789-98-3

 

Introduction

 

Description of Desmopressin Acetate: Desmopressin acetate (trade names: DDAVP, Stimate, Minirin) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as a tablet. Doctors prescribe Desmopressin most frequently for treatment of diabetes insipidus or nocturnal enuresis. Desmopressin (1-desamino-8-D-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin, a peptide containing nine amino acids. Medical use of Desmopressin acetate includes: (a) bed wetting; (b) nighttime urination; (c) clotting disorders; (d) diabetes insipidus  .

 

Specifications

 

Product Name	Desmopressin Acetate
Cas No.	16789-98-3
Molecular Formula	C46H64N14O12S2
Molecular Weight	1069.24
Purity (HPLC)	98.0%min.
Appearance	White powder
Single Impurity (HPLC)	0.5%max
Amino Acid Composition	±10% of theoretical
Peptide Content (N%)	≥80.0%
Water Content (Karl Fischer)	≤8.0%
Acetate Content (HPIC)	≤12.0%
MS (ESI)	Consistent
Mass Balance	95.0~105.0%

 

Function

 

Bed wetting
Desmopressin is used to treat nocturnal enuresis (bedwetting). It is usually prescribed in the form of oral desmopressin acetate, DDAVP. Children taking DDAVP have 2.2 fewer wet nights per week and are 4.5 times more likely to sleep without disruption compared with placebo.

US drug regulators banned treating nocturnal enuresis with desmopressin nasal sprays after two patients died and fifty-nine other patients suffered seizures. The patients were using desmopressin when they developed hyponatremia, an imbalance of the body's sodium levels.

Nighttime urination

Desmopressin has some benefit in adults who have problems with night time urination (known as nocturia).
Clotting disorders Desmopressin (DDAVP) stimulates the release of von Willebrand factor (vWF) from the Weibel-Palade_body bodies ofendothelial cells, thereby increasing the levels of vWF (as well as coagulant factor VIII) 3 to 5-fold. Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency) or severe hemophilia A.

 

Diabetes insipidus

Desmopressin is used in the treatment of central diabetes insipidus (DI), to replace endogenous antidiuretic hormone(ADH) that is missing in the central nervous system type of this disorder (decreased production of ADH from the posterior pituitary). It is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic DI.

 

 

Packaging & Shipping